Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Cash from Financing Activities came in at $16.5 million in Q2 2026, up 16925.51% on a YoY basis from N/an in Q2 2025, and up 86884.21% quarter-over-quarter from -$19000.0 in Q1 2026.
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has reported Cash from Financing Activities for 7 consecutive years, with $16.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities rose 16925.51% year-over-year to $16.5 million; the trailing twelve-month figure through Jun 2026 stood at $34.6 million (up 3650.87% YoY), and the FY2025 full-year result was $17.8 million, up 1122.14% from the prior year.
- Cash from Financing Activities grew to $16.5 million in Q2 2026 per DNA's latest filing, from -$19000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $97.8 million in Q4 2022 and bottomed at -$1.4 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $6.9 million across 5 years, with a median of -$270500.0 in 2023.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities slumped 175.29% in 2022, then jumped 16925.51% in 2026.
- Over 5 years, Cash from Financing Activities stood at $97.8 million in 2022, then plunged by 100.65% to -$632000.0 in 2023, then soared by 67.88% to -$203000.0 in 2024, then jumped by 4110.84% to $8.1 million in 2025, then soared by 102.52% to $16.5 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $16.5 million, -$19000.0, and $8.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | -214.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | -288.34 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | -8.12 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | -164.66 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 16.49 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 33,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 248,151.59 |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -118,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.49 Mn |
| Mar 31, 2026 | -19,000.00 |
| Dec 31, 2025 | 8.14 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Jun 30, 2025 | -98,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Dec 31, 2023 | -632,000.00 |
| Sep 30, 2023 | -315,000.00 |
| Jun 30, 2023 | -1.38 Mn |
| Mar 31, 2023 | -888,000.00 |
| Dec 31, 2022 | 97.76 Mn |
| Sep 30, 2022 | -391,000.00 |
| Jun 30, 2022 | -843,000.00 |
| Mar 31, 2022 | -1.19 Mn |
| Dec 31, 2021 | -11.04 Mn |
| Sep 30, 2021 | 1.55 Bn |